TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05558332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth-Nominated Support Teams for CHR
Description: Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk.
Study: NCT04345913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05133453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: drug intake three times daily for one year
Study: NCT05924295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Supplement
Description: Participants will be given 360mg/kg
Study: NCT06481891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin will be administered as a tablet(s), orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Study: NCT06038396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC118
Description: Dose A or dose B, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC118
Description: Dose A or dose B, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Fixed dose, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Fixed dose, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148
Description: Fixed dose, Q3W Other Names: RC148 injection
Study: NCT06469281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27T51
Description: Intravenous (IV) infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27T51
Description: Intravenous (IV) infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27T51
Description: Intravenous (IV) infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27T51
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion
Study: NCT05633654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablets administered orally
Study: NCT06432699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro osteoperforation
Description: one side used for mops while other side will be control in same patient
Study: NCT05858281

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Black adolescent girls (aged 12-17) will participate in an online survey and will be asked questions regarding their strengths, family, school and community experiences, sexual education knowledge, physical health and mental wellbeing, etc.

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Parents/guardians of Black girls (aged 12-17) and Black emerging adult women aged 18-22 will participate in individual interviews and will be asked questions about their understanding of Black girls' strengths and resources.

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Black adolescent girls (aged 12-17) will participate in a focus group and will be asked questions regarding their strengths, family, school and community resources, etc.
Study: NCT05517811

Intervention type: DIAGNOSTIC_TEST
Intervention: TEG indices
Description: Blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: TEG indices
Description: Blood samples
Study: NCT05825768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast MRI
Description: Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: standard breast imaging
Description: The control group that receives standard preoperative imaging only (breast ultrasound and mammography)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard breast imaging
Description: The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
Study: NCT06487208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of a digital cognitive aid in order to anticipate a critical situation
Description: Use of a digital cognitive aid in order to anticipate a critical situation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No intervention
Study: NCT06133309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Phenomenological Interview
Description: Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire
Study: NCT05539365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-type-1 Polarized Dendritic Cells
Description: Given IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05928585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIB210
Description: Experimental monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05746520

Intervention type: OTHER
Group type: OTHER
Intervention: Antibiotic
Description: Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.

Intervention type: OTHER
Group type: OTHER
Intervention: Antibiotic
Description: Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
Study: NCT05754333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous
Study: NCT06430333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Description: Mindfulness-based sleep program for pregnant women.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: Usual practices from real-world care experiences.
Study: NCT05203471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated care model
Description: The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
Study: NCT06488911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet (OCA 5 mg + BZF 400 mg SR)
Description: Participants will be administered with FDC tablets once daily.
Study: NCT05502718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Strengthening Exercises
Description: The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breathing and Rhythmic Coordination Exercises
Description: The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing and Rhythmic Coordination Exercises
Description: The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
Study: NCT06211036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion
Study: NCT06296368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preference Reporting to Improve Management and Experience (PRIME)
Description: PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities
Study: NCT05227612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive two doses of psilocybin (10mg, 25mg) as well as 12 sessions of CBT.
Study: NCT05141708

Intervention type: DRUG
Intervention: Talazoparib
Description: Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
Study: NCT06193200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo encapsulated in autologous erythrocytes and administered via IV infusion
Study: NCT05275478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally
Study: NCT05924295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale
Description: Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine Analysis
Description: Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
Study: NCT05275478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG908
Description: TNG908, a selective PRMT5 inhibitor, will be administered orally
Study: NCT05851443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povorcitinib
Description: povorcitinib
Study: NCT05804656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKDB-501A
Description: Intramuscular injection CKDB-501A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Intramuscular injection Botox®
Study: NCT05478434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortico-cortical stimulation plus robot-assisted therapy
Description: 15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cortico-cortical stimulation plus robot-assisted therapy
Description: 15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
Study: NCT05594927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huachansu
Description: 1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
Study: NCT05749510

Intervention type: OTHER
Intervention: NCRT+TME
Description: The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
Study: NCT05921682

Intervention type: OTHER
Intervention: observation
Description: This study is an observational study. Patients will receive conventional cooling measures and organ function support.
Study: NCT05016661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Study: NCT06643234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral hernia repair
Description: Comparative between both techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral hernia repair
Description: Comparative between both techniques
Study: NCT05851443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povorcitinib
Description: povorcitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povorcitinib
Description: povorcitinib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS-LABA
Description: Background Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS-LABA
Description: Background Therapy
Study: NCT05450601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2104-2
Description: Placebo drug. Take once daily for 6 weeks orally
Study: NCT05851443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS-LABA
Description: Background Therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS-LABA
Description: Background Therapy
Study: NCT06139328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845
Study: NCT06049784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Biofeedback using self operated home ultrasound device
Description: participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Biofeedback using ultrasound at hospital
Description: A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
Study: NCT06139328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845
Study: NCT05796297

Intervention type: DEVICE
Intervention: Transcutaneous Capnography
Description: Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation

Intervention type: DEVICE
Intervention: Transcutaneous Capnography
Description: Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
Study: NCT04934384

Intervention type: DIAGNOSTIC_TEST
Intervention: prehospital extended focused assessment sonography for trauma
Description: Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients

Intervention type: DIAGNOSTIC_TEST
Intervention: prehospital extended focused assessment sonography for trauma
Description: Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
Study: NCT04916366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping in a bandage to treat musculoskeletal pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional bandage
Description: It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
Study: NCT05634733

Intervention type: OTHER
Intervention: Treatment of Sepsis
Description: Patients will have standard care of sepsis